Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice.
Toxicol Appl Pharmacol
; 273(2): 325-34, 2013 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-24055643
Palavras-chave
5-aminoimidazole-4-carboxamide ribonucleoside; ACC; AICAR; AID; AMP-activated protein kinase; AMPK; Activator; Allosteric; CBS; CCCP; CNTF; CaMKKα/ß; G6Pase; GBD; GSK3ß; IKKß; IκB kinase ß; KD; MAP/microtubule affinity-regulating kinase 2; MARK2; MELK; Maternal Embryonic Leucine zipper Kinase; Metabolic syndrome; Orally effective; PEPCK; RER; S. pombe; SPA; Schizosaccharomyces pombe; Small-molecule; TAK1; acetyl-CoA carboxylase; autoinhibitory domain; calmodulin-dependent protein kinase kinase α/ß; carbonyl cyanide m-chlorophenylhydrazone; ciliary neurotrophic factor; cystathionine beta synthase; glucose-6-phosphatase; glycogen synthase kinase 3ß; glycogen-binding domain; intraperitoneal glucose tolerance test; ipGTT; kinase domain; phosphoenolpyruvate carboxykinase; respiratory exchange ratio; scintillation proximity assay; transforming growth factor-ß-activated kinase1
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus
/
Proteínas Quinases Ativadas por AMP
/
Hipoglicemiantes
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Toxicol Appl Pharmacol
Ano de publicação:
2013
Tipo de documento:
Article